| Prev Close | 11.10 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 8.55 / 11.43 |
| Avg Volume | 455.30K |
| Exchange | NASDAQ |
| Shares Outstanding | 52.19M |
| Market Cap | 579.33M |
| EPS | 0.60 |
| P/E Ratio | 13.70 |
| Div & Yield | N.A. (N.A) |
The most recent short interest data has been released for the 06/15/2017 settlement date, which shows a 721,576 share decrease in total short interest for SciClone Pharmaceuticals, Inc. , to 846,255, a decrease of 46.02% since 05/31/2017.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of SciClone...
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased SciClone Pharmaceuticals Inc.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of SciClone...
Generic drugmakers are likely to limit themselves to acquisitions of small- and mid-sized companies in the immediate future because of over-leveraging and turmoil in the executive ranks..
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased SciClone Pharmaceuticals Inc.
In trading on Friday, shares of SciClone Pharmaceuticals, Inc. crossed above their 200 day moving average of $9.98, changing hands as high as $10.04 per share.
The approval marks the first time that an immunotherapy has been combined with another drug to kill cancer cells more effectively.
The most recent short interest data has been released for the 10/31/2016 settlement date, which shows a 462,133 share decrease in total short interest for SciClone Pharmaceuticals, Inc. , to 2,167,158, a decrease of 17.58% since 10/14/2016.
Investors considering a purchase of SciClone Pharmaceuticals, Inc. shares, but tentative about paying the going market price of $9.03/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
The most recent short interest data has been released for the 07/29/2016 settlement date, which shows a 528,413 share decrease in total short interest for SciClone Pharmaceuticals, Inc. , to 1,960,649, a decrease of 21.23% since 07/15/2016.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors in SciClone Pharmaceuticals, Inc. saw new options begin trading this week, for the August 19th expiration.
Trade-Ideas LLC identified SciClone Pharmaceuticals (SCLN) as a weak on high relative volume candidate
Trade-Ideas LLC identified SciClone Pharmaceuticals (SCLN) as a weak on high relative volume candidate
Oil controls the market, and Cramer is watching stocks to see which you should be buying.
Cramer is no fan of J.C. Penney and says NCR is up too much.
Investors in SciClone Pharmaceuticals, Inc. saw new options become available this week, for the May 20th expiration.
Investors considering a purchase of SciClone Pharmaceuticals, Inc. shares, but tentative about paying the going market price of $9.74/share, might benefit from considering selling puts among the alternative strategies at their disposal.
In trading on Friday, shares of SciClone Pharmaceuticals, Inc. crossed above their 200 day moving average of $8.58, changing hands as high as $8.93 per share.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Stocks with insider trader activity include MW, SCLN and ATHN
